

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-100035-PIP01-21

Scope of the Application

Active Substance(s)

POVIDONE-IODINE; ISOPROPYL ALCOHOL

Condition(s)

Prevention of infection prior to invasive procedures

Pharmaceutical Form(s)

Cutaneous solution

Route(s) of Administration

Cutaneous use

Name / Corporate name of the PIP applicant

Becton Dickinson UK Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Becton Dickinson UK Ltd submitted to the licensing authority on 16/02/2021 11:53 GMT an application for a Waiver

The procedure started on 29/03/2021 09:00 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
gov.uk/mhra

Final Decision Letter

MHRA-100035-PIP01-21

Of 06/05/2021 09:06 BST

On the adopted decision for POVIDONE-IODINE; ISOPROPYL ALCOHOL (MHRA-100035-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Waiver for POVIDONE-IODINE; ISOPROPYL ALCOHOL, Cutaneous solution , Cutaneous use .

This decision is addressed to Becton Dickinson UK Ltd, 1030 Eskdale Road, Winnersh, Wokingham, United Kingdom, RG41 5TS

ANNEX I

1. Waiver

1.1 Condition:

Prevention of infection prior to invasive procedures
--

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not applicable

2.2 Indication(s) targeted by the PIP:

Not applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not applicable

2.4 Pharmaceutical Form(s):

Not applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	